Official title and information are available only for Plus and Premium subscribers.
Patent Granted Blocking CXCR1 (e.g., with repertaxin[3]) inhibits some human breast cancer stem cells (in vitro and in mice).[4] CXCR1 can be cleaved and inactivated by Neutrophil Derived Serine Proteases (NSPs), leading to neutrophil dysfunction and impaired bacterial killing in Cystic Fibrosis lung disease.
To see the additional information details please login and subscribe to a Plus or Premium account.
